Hodgkin Lymphoma - Pipeline Review, H2 2015

Date: August 19, 2015
Pages: 322
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H564BDF6234EN
Leaflet:

Download PDF Leaflet

Hodgkin Lymphoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Hodgkin Lymphoma - Pipeline Review, H2 2015’, provides an overview of the Hodgkin Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Hodgkin Lymphoma Overview
Therapeutics Development
Pipeline Products for Hodgkin Lymphoma - Overview
Pipeline Products for Hodgkin Lymphoma - Comparative Analysis
Hodgkin Lymphoma - Therapeutics under Development by Companies
Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes
Hodgkin Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hodgkin Lymphoma - Products under Development by Companies
Hodgkin Lymphoma - Products under Investigation by Universities/Institutes
Hodgkin Lymphoma - Companies Involved in Therapeutics Development
4SC AG
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
ADC Therapeutics Sarl
Affimed Therapeutics AG
Aptose Biosciences Inc.
Arbutus Biopharma Corporation
AVEO Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.
Biogenomics Limited
Bristol-Myers Squibb Company
Celgene Corporation
Cell Medica Limited
Cellular Biomedicine Group, Inc.
Constellation Pharmaceuticals, Inc.
Curis, Inc.
Gamida Cell Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Johnson & Johnson
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Molecular Templates Inc.
NantKwest, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmacyclics, Inc.
Philogen S.p.A.
Seattle Genetics, Inc.
Selvita SA
Sigma-Tau S.p.A.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Syndax Pharmaceuticals, Inc.
TG Therapeutics, Inc.
Theravectys SA
Hodgkin Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abexinostat hydrochloride - Drug Profile
acalisib - Drug Profile
ADCT-301 - Drug Profile
AFM-13 - Drug Profile
Alocrest - Drug Profile
aNK Program - Drug Profile
APTO-253 - Drug Profile
azacitidine - Drug Profile
BMS-986016 - Drug Profile
BPX-501 - Drug Profile
brentuximab vedotin - Drug Profile
CBM-C30.1 - Drug Profile
Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
Cell Therapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile
Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile
CMD-003 - Drug Profile
CPI-0610 - Drug Profile
CUDC-907 - Drug Profile
Dendritic Cell Therapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile
Dendritic Cell Therapy for Oncology - Drug Profile
entinostat - Drug Profile
Ferritarg - Drug Profile
ficlatuzumab - Drug Profile
haNK Program - Drug Profile
INCB-39110 - Drug Profile
INCB-40093 - Drug Profile
Indimitecan - Drug Profile
Indotecan hydrochloride - Drug Profile
interferon alfa-2b (recombinant) - Drug Profile
Iomab-B - Drug Profile
ixazomib citrate - Drug Profile
JNJ-40346527 - Drug Profile
MK-2206 - Drug Profile
mocetinostat - Drug Profile
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile
Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile
NiCord - Drug Profile
nivolumab - Drug Profile
NSC-678515 - Drug Profile
panobinostat - Drug Profile
pembrolizumab - Drug Profile
pevonedistat hydrochloride - Drug Profile
procarbazine hydrochloride - Drug Profile
radretumab - Drug Profile
Recombinant Proteins for Melanoma and Hodgkin's Lymphoma - Drug Profile
resminostat - Drug Profile
ricolinostat - Drug Profile
RP-323 - Drug Profile
ruxolitinib phosphate - Drug Profile
SEL-24B489 - Drug Profile
SL-101 - Drug Profile
SL-501 - Drug Profile
temsirolimus - Drug Profile
TGR-1202 - Drug Profile
TKM-PLK1 - Drug Profile
Vaccine for EBV Associated Cancer - Drug Profile
Hodgkin Lymphoma - Recent Pipeline Updates
Hodgkin Lymphoma - Dormant Projects
Hodgkin Lymphoma - Discontinued Products
Hodgkin Lymphoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hodgkin Lymphoma, H2 2015
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2015
Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H2 2015
Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015
Hodgkin Lymphoma - Pipeline by Aptose Biosciences Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Arbutus Biopharma Corporation, H2 2015
Hodgkin Lymphoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Biogenomics Limited, H2 2015
Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015
Hodgkin Lymphoma - Pipeline by Celgene Corporation, H2 2015
Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H2 2015
Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Curis, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H2 2015
Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Incyte Corporation, H2 2015
Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H2 2015
Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H2 2015
Hodgkin Lymphoma - Pipeline by NantKwest, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2015
Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Hodgkin Lymphoma - Pipeline by Pfizer Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H2 2015
Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Selvita SA, H2 2015
Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2015
Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015
Hodgkin Lymphoma - Pipeline by Theravectys SA, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015
Hodgkin Lymphoma - Dormant Projects, H2 2015
Hodgkin Lymphoma - Dormant Projects (Contd..1), H2 2015
Hodgkin Lymphoma - Dormant Projects (Contd..2), H2 2015
Hodgkin Lymphoma - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Hodgkin Lymphoma, H2 2015
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015
Skip to top


Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 710 pages

Ask Your Question

Hodgkin Lymphoma - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: